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Background: Polycystic ovary syndrome (PCOS) is associated with obesity and increased cardiovascular (CV) risk
markers. In this study our aim was to assess the effects of six months treatment with liraglutide 1.8 mg od on
obesity, and CV risk markers, particularly platelet function, in young obese women with PCOS compared to controls
of similar age and weight.
Methods: Carotid intima-media wall thickness (cIMT) was measured by B-mode ultrasonography, platelet function
by flow cytometry, clot structure/lysis by turbidimetric assays and endothelial function by ELISA and post-ischaemic
reactive hyperemia (RHI). Data presented as mean change (6-month – baseline) ± standard deviation.
Results: Nineteen obese women with PCOS and 17 controls, of similar age and weight, were recruited; baseline
atherothrombotic risk markers did not differ between the two groups. Twenty five (69.4%) participants completed
the study (13 PCOS, 12 controls). At six months, weight was significantly reduced by 3.0 ± 4.2 and 3.8 ± 3.4 kg in the
PCOS and control groups, respectively; with no significant difference between the two groups, P = 0.56. Similarly,
HOMA-IR, triglyceride, hsCRP, urinary isoprostanes, serum endothelial adhesion markers (sP-selectin, sICAM and
sVCAM), and clot lysis area were equally significantly reduced in both groups compared to baseline. Basal platelet
P-selectin expression was significantly reduced at six months in controls −0.17 ± 0.26 but not PCOS −0.12 ± 0.28;
between groups difference, 95% confidence interval = −0.14 – 0.26, P = 0.41. No significant changes were noted in
cIMT or RHI.
Conclusions: Six months treatment with liraglutide (1.8 mg od) equally affected young obese women with PCOS
and controls. In both groups, liraglutide treatment was associated with 3–4% weight loss and significant reduction
in atherothrombosis markers including inflammation, endothelial function and clotting. Our data support the use of
liraglutide as weight loss medication in simple obesity and suggest a potential beneficial effect on platelet function
and atherothrombotic risk at 6 months of treatment.
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Polycystic ovary syndrome (PCOS) is the most common
endocrine disorder in women of reproductive age [1].
Women with PCOS commonly present with oligomen-
orrhoea, hirsutism, subfertility and obesity [1]. Obesity
may play a role in the aetiology of PCOS and weight loss
has been found to improve many clinical features of
PCOS including menses regularity and fertility [2].
Despite the lack of long term cardiovascular (CV) out-
come data, PCOS has been linked to several CV risk
markers including type 2 diabetes [3], increased carotid
intima-media wall thickness (cIMT) [4] and impaired
platelet function [5,6]. We have reported recently that
obesity, rather than the PCOS phenotype, appears to
have the greatest impact on atherothrombotic risk para-
meters [7]. Weight loss has been found to reduce many
CV risk markers in PCOS including inflammation, and
insulin resistance (IR) [8]. Furthermore, in a recent study
in healthy obese men and women, weight loss improved
platelet function, by increasing platelets’ sensitivity to
the inhibitory effect of prostacyclin (PGI2) and nitric
oxide (NO) in aggregation [9]. However, studies investi-
gating the effect of weight loss on platelet function and
cIMT in obese women with PCOS are lacking.
Lifestyle modifications and orlistat therapy are the only
currently licensed treatments for obese women with
PCOS not suitable for bariatric surgery. However, their
efficacy is limited by the low compliance rate [10] and
gastrointestinal side effects with orlistat. Recently, a glu-
cagon like peptide-1 (GLP-1) mimetic, exenatide, has
been found to improve weight and menses regularity in
obese women with PCOS [11]. Liraglutide is a long acting
GLP-1 analogue with 97% resemblance to the native GLP-1
and seems to be better tolerated than exenatide [12]. Simi-
lar to native GLP-1, it causes glucose dependent insulin
secretion, promotes weight loss [13,14], and may subse-
quently improve IR. Although liraglutide is currently only
licensed for the treatment of people with type 2 diabetes,
it represents an attractive option for the treatment of
obese women with PCOS.
The primary aim of this study was to assess whether six
months treatment with liraglutide 1.8 mg once a day (od)
would have an impact on body weight, platelet function
and cIMT in young obese women with PCOS compared
to controls of similar age and weight. Study secondary
outcomes were to measure changes in anthropometric pa-
rameters, IR, lipids profile, inflammation, oxidative stress,
clot structure/lysis, and endothelial function.
We hypothesised that women with PCOS and controls
respond equally to treatment with liraglutide.
Study design
Interventional study of young obese women with PCOS
and controls of similar age and weight. The study wasapproved by the Leeds (East) Research Ethics Committee
and an informed consent was given by all study partici-
pants before participation.
Study participants
The baseline characteristics of study participants and
their selection prior to treatment have been described
[7]. Women with PCOS were recruited from the en-
docrine clinic and controls were recruited through an
advertisement in the local newspaper. Subjects were in-
vited for a screening visit if they had a body mass index
(BMI) between 30–45 kg/m2, were between 18–45 years
of age and on no medications. No one to one matching
was performed. PCOS was diagnosed according to the
Rotterdam criteria [15]. Participants with an alcohol in-
take of >14 units/week were also excluded. The metabolic
syndrome was defined according to the International
Diabetes Federation criteria 2006 [16]. Participants who
fulfilled the study inclusion/exclusion criteria, PCOS and
controls, were treated with liraglutide 0.6 mg od subcuta-
neous injection for 1 week, 1.2 mg od for one week and
then 1.8 mg od thereafter for six months. Study par-
ticipants received no dietary advice. Participants were seen
at baseline, three and six months after starting the
treatment.
Methods
A detailed description of the methods used for mea-
suring anthropometric, biochemical markers, cIMT, plate-
let, endothelial and clotting functions have been described
[7]. A brief description is outlined below.
Biochemical markers
Venous blood samples were collected in the morning
after a minimum of a 10 h fast and samples were stored
at −80°C until batch analysis. Overnight urine samples
were collected and aliquots stored at −20°C until batch
analysis. Biochemical markers measured included high
sensitivity C-reactive protein (hsCRP), testosterone, sex
hormone binding globulin (SHBG), free androgen index
(FAI), lipids profile, and urinary isoprostanes (8-iso
PGF2α). Fasting plasma glucose (FPG) and insulin were
measured to calculate the homeostatic model assessment
of insulin resistance (HOMA-IR): FPG (mmol/L) X fas-
ting insulin (iu/ml))/22.5 and β-cell function (HOMA-β):
20 X fasting insulin/(FPG – 3.5) [17].
Carotid intima-media wall thickness (cIMT)
cIMT was measured using a Toshiba Xario 15 scanner
(Toshiba Medical Systems, Tokyo, Japan) equipped with
11-MHz linear imaging probe. The cIMT measurements
were performed in accordance with recommendations by
Mannheim consensus, 2006 [18]. All measurements were
performed by the same trained operator. Reproducibility
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who underwent 2 ultrasound examinations within 4 weeks
period using Bland Altman plot, mean difference = −0.002
(95% limits of agreement = −0.055, 0.059); intraclass cor-
relation coefficient (ICC) = 0.95 (95% CI = 0.90, 0.99).
Platelet function
Fluorescein isothiocyanate (FITC)-conjugated anti hu-
man CD42b antibody, phycoerythrin (PE)-conjugated
anti human CD62P, FITC-anti IgG1k and PE-anti IgG1k
isotope controls were obtained from BD bioscience
(Oxford, UK). FITC-anti human fibrinogen was obtained
from Dako (Stockport, UK). Prostacyclin I2 (PGI2) was ob-
tained from Cayman (USA) and Adenosine 5’-diphosphate
(ADP) from Sigma (Poole, UK).
Platelet function was analysed in whole blood by flow
cytometry according to the methods described by Riba
et al. [19]. Platelet population was identified by their for-
ward and side-scatter characteristics and confirmed by the
expression of platelet specific surface marker CD42b.
P-selectin surface expression, a marker of platelet α-granule
content release, and fibrinogen binding, a marker of platelet
activation, were calculated from 10,000 platelet events. In
brief, 5 μl of citrated blood was diluted in 50 μl of modified
Tyrodes buffer (150 mM NaCl, 5 mM HEPES [N-2-hy-
droxyethylpiperazine-N’-2-ethanesulfonic acid], 0.55 mM
NaH2PO4, 7 mM NaHCO3, 2.7 mM KCl, 0.5 mM MgCl2,
5.6 mM glucose, pH 7.4) and mixed with 2 μL of the ap-
propriate FITC or PE labelled antibody. Samples were
fixed with 500 μl of 0.2% paraformaldehyde and analysed
by flow cytometry (BD FACSAria). In some cases, samples
were incubated with ADP in the presence and absence of
PGI2 before fixation.
Endothelial function
Endothelial function was examined by measuring the
post-ischaemic reactive hyperaemic index (RHI) using
Endo-PAT2000 (Itamar Medical Ltd, Israel) [20]. The
serum concentrations of endothelial adhesion markers
sP-selectin, intercellular adhesion molecule-1 (sICAM-1),
and vascular cell adhesion molecule-1 (sVCAM-1) were
measured by ELISA as per manufacturer’s protocol.
Clot formation/lysis
Clot structure analysis was measured using turbidimetric
analysis as previously described [21]. The clot parame-
ters assessed included lag phase, maximum absorbance
(MA), lysis time (LT), clot formation time and lysis area
(LA). Higher MA of plasma clots, longer LT and larger
LA are associated increased CV risk [22].
Power calculations and statistical analysis
The sample size for platelet function was powered using
the Mann–Whitney U test for continuous data [23] andan ‘effect size’ between 1.12–1.25 for changes in
P-selectin expression in unstimulated samples [24,25]. A
sample size of 18 per group allow us to detect an effect
size of 1.12 (or larger) with 80% power, 20% attrition
and 5% significance (two-tailed) between cases and con-
trols. As variations within groups are usually smaller
than between groups, this study was adequately powered
to detect differences’ pre/post treatment.
Continuous data were summarised by the mean ±
standard deviation (SD), and categorical data by number
(percentages). Data were checked for normality using
Kolmogorov-Smirnov test. Differences between groups
at baseline were analysed using the independent t-test
for continuous data (or Mann–Whitney U test for non-
normally distributed data). Frequency distributions’ were
analysed using Chi-square test. Between groups’ compar-
isons after intervention were as follows: for each group
(PCOS and controls) a difference between baseline and
6 months was calculated. The between group differences
were compared using the independent t-test (or Mann–
Whitney U test for non-normally distributed data).
Within groups analysis (baseline vs. six months) was
performed using the dependent t-test for continuous
data (or Wilcoxon signed-rank test for non-normally
distributed data). Data were analysed using intention to
treat analysis with missing values for sequential data
imputed by carrying the last observation forward [26].
Statistical analysis was performed using the PASW
statistics 19 package (SPSS Inc., Chicago, USA). A
two tailed P value of <0.05 was considered statistically
significant.Results
Baseline characteristics
Fifty one women were screened, 36 recruited (19 PCOS,
17 normal controls). Fifteen women were excluded as
they had; idiopathic hirsutism (five), hypothyroidism
(one), BMI <30 kg/m2 (one), no trans-vaginal ultrasound
(TV USS) scan was done (two), ovaries not visible on
TV USS (one), oligomenorrhoea without PCOS (one),
and repeatedly missing the initial study visit (four).
The PCOS and control groups had similar age 33.9 ± 6.7
vs. 33.5 ± 7.1 years, weight 102.1 ± 17.1 vs. 100.4 ± 15.1 kg,
BMI 37.9 ± 5.0 vs. 36.5 ± 4.6 kg/m2, and waist 112.7 ± 12.6
vs. 112.4 ± 9.4 cm, respectively. The PCOS group
had higher testosterone 1.3 ± 0.4 vs. 0.9 ± 0.3 nmol/L
(P = 0.01), FAI 4.4 ± 2.0 vs. 2.6 ± 1.2 (P = 0.01), fasting
insulin 22.0 ± 9.4 vs. 16.1 ± 5.6 iu/ml (P = 0.03) and
HOMA-IR 5.1 ± 2.6 vs. 3.5 ± 1.3 (P = 0.03) compared to
controls at baseline (Table 1). cIMT, platelet function, clot
formation/lysis, and endothelial function did not signifi-
cantly differ between the two groups at baseline; data re-
cently published [7].
Table 1 Anthropometric, metabolic and biochemical parameters at baseline and after treatment with liraglutide
Variable PCOS (n = 19) Controls (n = 17) PCOS Controls Between groups difference
Baseline mean (SD) Baseline mean (SD) 6-months-baseline 6-months-baseline 95% CI P-value
Weight (kg) 102.1 (17.1) 100.4 (15.1) −3.0† −3.8† −1.9 – 3.4 0.56
BMI (kg/m2) 37.9 (5.0) 36.5 (4.6) −1.0† −1.4† −0.6 – 1.3 0.43
Waist (cm) 112.0 (12.6) 112.3 (9.7) −1.1 −1.4 −2.4 – 3.2 0.78
Systolic BP (mmHg) 121 ± 13.0 126 ± 12.9 0.0 −4.4 −2.9 – 11.7 0.23
Diastolic BP (mmHg) 75 (7.6) 79 (6.6) 0.3 −3.9 −2.1 – 10.4 0.19
Average HR (bpm) 67.7 (7.7) 67.3 (9.0) 3.0 4.0† −5.0 – 4.0 0.77
Metabolic syndrme 10 (52.6%) 6 (35.3%) −4.0 0.0
Testosterone (nmol/L) 1.3 (0.4) 0.90 (0.3)* −0.03 0.04 −0.4 – 0.2 0.63
FAI 4.4 (2.0) 2.6 (1.2)* 0.09 −0.06 −1.2 – 1.5 0.76
SHBG (nmol/L) 33.2 (14.6) 38.1 (14.4) −2.4 2.3 −10.9 – 1.7 0.50
FPG (mmol/L) 5.1 (0.6) 4.9 (0.4) −0.2† −0.3† −0.2 – 0.4 0.40
Insulin (iu/ml) 22.0 (9.4) 16.1 (5.6)* −2.6† −3.4† −2.3 – 3.9 0.61
HOMA-IR 5.1 (2.6) 3.5 (1.3)* −0.8† −0.9* −0.6 – 0.9 0.70
HOMA-β 303 (135) 255 (114) 11.2 10.7 −70.0 – 70.9 1
hsCRP (mg/L) 6.2 (8.7) 5.1 (3.4) −1.9† −1.2† −4.3 – 2.9 0.21
Total chol (mmol/L) 5.0 (0.8) 5.1 (1.0) −0.1 −0.02 −0.4 – 0.3 0.64
LDL (mmol/L) 3.2 (0.6) 3.3 (0.9) 0.06 0.08 −0.3 – 0.3 0.89
HDL (mmol/L) 1.2 (0.2) 1.3 (0.2) −0.02 −0.04 −0.1 – 0.2 0.84
Tri (mmol/L) 1.4 (0.7) 1.4 (0.7) −0.3† −0.2† −0.4 – 0.2 0.56
Chol/HDL 4.4 (0.9) 4.1 (0.8) −0.03 0.1 −0.6 – 0.3 0.37
Isoprostane (ng/ml) 0.81 (0.53) 0.58 (0.57) −0.5† −0.4† −0.5 – 0.3 0.64
Fibrinogen (mg/ml) 3.8 (1.2) 3.5 (1.0) 0.02 −0.03 −0.4 – 0.5 0.84
cIMT 0.51 (0.05) 0.48 (0.06) 0.002 0.004 −0.01 – 0.02 0.41
RHI 1.9 (0.5) 1.9 (0.5) −0.01 0.1 −0.8 – 0.6 0.68
sP-selectin (ng/ml) 135.9 (40.3) 126.4 (25.5) −36.4† −47.1† −13.7 – 35.1 0.38
sICAM-1 (ng/ml) 302.8 (53.3) 302.1 (36.9) −53.6† −78.2† −16.8 – 66.0 0.24
sVCAM-1 (ng/ml) 3384 (379) 3449 (404) −1600† −1824† −335 – 782 0.42
BMI, body mass index; BP, blood pressure; HR, heart rate; bpm, beat per minute; FAI, free androgen index; SHBG, sex hormone binding globulin; FPG, fasting
plasma glucose; HOMA-IR, homeostatic model assessment-insulin resistance; HOMA-β, homeostatic model assessment-β cell function; hsCRP, high sensitivity
C-reactive protein; LDL, low density lipoprotein; HDL, high density lipoprotein; Tri, triglycerides; Chol, cholesterol; cIMT, carotid intima-media wall thickness;
RHI, reactive hyperemic index; sICAM, soluble intercellular adhesion molecule-1; sVCAM, soluble vascular cell adhesion molecule-1. Data are mean (standard
deviation (SD)) or number (percentage). *Significant difference between the two groups at baseline, P < 0.05. †Significant within group difference, 6-month vs.
baseline, P < 0.05.
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Twenty five women, 69%, completed the study (13 PCOS,
and 12 controls). Eleven women dropped out because of:
nausea and vomiting (four), loss of follow up (four), fre-
quently missing study drug (one), change in personal cir-
cumstances (one), and pregnancy (one).
Demographics
Following 6 months of treatment with liraglutide 1.8 mg
od body weight was reduced by 3.0 ± 4.2 (P < 0.01) and
3.8 ± 3.4 kg (P < 0.01); BMI by 1.0 ± 1.5 (P = 0.01) and
1.4 ± 1.2 kg/m2 (P < 0.01); while average heart rate
increased by 3 ± 7 (P = 0.051) and 4 ± 7 beats per minute(bpm) (P = 0.02) in the PCOS and control groups, res-
pectively. There was no significant change in waist cir-
cumference, systolic and diastolic blood pressure, or in
the prevalence of the metabolic syndrome (Table 1). Be-
tween groups comparisons were not significant (Table 1).
Biochemical profile
At 6 months FPG, fasting insulin, HOMA-IR, hsCRP, tri-
glycerides, and urinary isoprostane significantly reduced
in both groups. There was no significant change in other
biochemical markers including testosterone, SHBG, FAI,
HOMA-β or cholesterol (Table 1). Between groups com-
parisons were not significant (Table 1).
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There was no significant change in average cIMT at
baseline compared to 6 months in either group. Simi-
larly, between groups changes were not significant
(Table 1).
Platelet function
Following 6 months treatment with liraglutide there was
significant inhibition of P-selectin expression in un-
stimulated samples in the control group, compared to
baseline, without change in fibrinogen binding (Table 2).
P-selectin expression and fibrinogen binding levels were
unchanged in the PCOS group at 6 months compared to
baseline. Similarly, platelet response to activation by
ADP (0.1 - 10 μM) or to inhibition by PGI2 (1 - 100nM)
were unchanged at 6 months in either group (Table 2).
Between groups changes were not significant (Table 2).Table 2 Platelet function, activation and sensitivity to prostac
treatment with liraglutide
Variable PCOS Controls
Baseline mean (SD) Baseline mean (SD)
Platelets P-selectin expression
Basal activation 0.52 (0.3) 0.42 (0.2)
ADP 0.1 μM 3.1 (2.9) 2.8 (2.1)
ADP 1 μM 40.2 (14.5) 44.0 (13.5)
ADP 10 μM 61.6 (13.6) 66.9 (13.1)
% inhibition by PGI2:
1 nM 17.5 (14.1) 17.8 (10.9)
10 nM 65.5 (11.7) 66.5 (9.6)
100 nM 79.3 (6.5) 77.4 (7.1)
Platelets fibrinogen binding
Basal activation 0.97 (0.4) 0.83 (0.3)
ADP 0.1 μM 9.7 (10.0) 7.7 (7.1)
ADP 1 μM 55.9 (18.4) 55.8 (19.0)
ADP 10 μM 73.7 (14.6) 76.2 (11.7)
% inhibition by PGI2:
1 nM 41.5 (23.2) 46.7 (17.6)
10 nM 95.8 (2.3) 96.8 (2.1)
100 nM 97.8 (1.1) 98.0 (1.4)
Clot function/lysis
Lag phase (sec) 379 (64) 380 (45)
Lysis area (au) 586 (292) 538 (177)
Maximum absorbance (au) 0.39 (0.1) 0.41 (0.1)
Clot formation time (sec) 609 (190) 583 (144)
Lysis time (sec) 766 (204) 743 (117)
Platelet surface expression (% of positive cells) of P-selectin and fibrinogen binding we
ADP 0.1-10 μM for 20 minutes before fixing with 0.2% paraformaldehyde. For platelet
90 seconds before; stimulation with ADP 10 μM and fixing at 20 minutes for P-selectin
binding. Data are presented as mean (standard deviation (SD)). ADP, adenosine-5’-diph
baseline were not statistically significant (all P values were >0.05). †Significant within gClot function/lysis
At six months, clot lag phase significantly increased
and LA reduced in both groups compared to baseline
(Table 2). However, other markers did not significantly
change in either group including clot LT, clot formation
time, and clot MA (Table 2). There was no significant
change in fibrinogen levels at 6 months compared to
baseline (Table 1). Between groups changes were not sig-
nificant (Table 2).
Endothelial function
There was no significant change in RHI, at six months
compared to baseline, in either group (Table 1). Serum
markers of endothelial function sP-selectin, sVCAM-1
and sICAM-1 significantly reduced after treatment in
both groups (Table 1). Between groups changes were not
significant.yclin, and clotting function/lysis at baseline and after
PCOS Controls Between groups difference
6-months-baseline 6-months-baseline 95% CI P-value
−0.12 −0.17† −0.14 – 0.26 0.41
−0.09 −0.16 −1.6 – 1.7 0.42
0.2 −1.1 −4.8 – 7.3 0.74
−0.1 2.9 −8.7 – 2.8 0.30
3.4 6.0 −9.8 – 4.6 0.80
3.5 3.0 −7.1 – 8.1 0.67
1.7 2.5 −5.6 – 4.0 0.74
−0.04 0.09 −0.4 – 0.13 0.31
1.6 −2.6 −0.06 – 8.4 0.13
0.6 −4.6 −3.4 – 13.8 0.30
1.1 −4.0 −0.95 – 11.2 0.10
5.6 3.6 −13.7 – 17.6 0.90
0.7 0.1 −0.9 – 2.5 0.28
0.5 0.2 −0.4 – 1.7 0.21
96† 139† −99 – 12.8 0.13
−108† −100† −139 – 124 0.59
−0.01 −0.03 −0.03 – 0.06 0.49
69 40 −83 – 140 0.61
7.1 20.9 −136 – 108 0.82
re measured in unstimulated samples (basal activation) and after stimulation with
sensitivity to PGI2, samples were pre incubated with PGI2 1, 10, and 100 nM for
expression; or stimulation with ADP 1 μM and fixing at 5 minutes for fibrinogen
osphate; PGI2, prostacyclin; sec, seconds; au, arbitrary unit. Comparisons at
roup change, 6-month vs. baseline, P < 0.05.
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Our data suggest that young obese women with PCOS
and controls, of similar age and weight, respond equally
to treatment with liraglutide. In both groups, six months
treatment with liraglutide (1.8 mg od) was associated
with a small, though significant, 3 – 4% weight loss that
was associated with significant reductions in IR, inflam-
mation, oxidative stress and improvement in several CV
risk markers in young obese women with and without
PCOS. Our findings are important as the majority of
previous reports suggest the need for moderate weight
loss (≥10%) to achieve reduction in atherothrombotic
risk [9,27].
The weight loss of 3 – 4% achieved in our study with
liraglutide 1.8 mg od is in accord with other published
data [13], and although a higher dose of liraglutide
might have resulted in more pronounced weight loss
[14], we have chosen the highest dose currently licensed
for the treatment of people with type 2 diabetes [28]; a
dose with well-known safety profile and adverse re-
actions. The effects of liraglutide on weight loss are
thought to be mainly mediated through delayed gastric
emptying and reduced appetite, rather than a change in
energy expenditure [29]. While its effects on glucose
metabolism are secondary to an increase in insulin se-
cretion in a glucose-dependent manner, suppression of
glucagon secretion, enhanced hepatic insulin action, and
reduced β-cell apoptosis [30-32]. Similar to native GLP-1,
liraglutide is widely believed to exert its actions through
the GLP-1 receptor (GLP-1R) and the activation of cyclic
adenosine monophosphate (cAMP) dependent pathway
[28]. This is supported by the wide expression of GLP-1R
including in the pancreas, stomach, and brain [32]. How-
ever, the underlying mechanisms for GLP-1 mediated
weight loss remain poorly understood and may involve
direct, GLP-1R mediated, and indirect, e.g. neuronal, path-
ways [32].
This is the first study to examine the impact of treat-
ment with GLP-1 analogues on platelet function in
obese women with or without PCOS. In this study, there
was a significant inhibition in basal platelet P-selectin
expression after treatment with liraglutide in the control
group only. P-selectin is only expressed on the platelet
surface membrane after a granule secretion (i.e. platelet
activation) [33]. It mediates adhesion of activated plate-
lets to neutrophils and monocytes [34]; plays a central
role in platelet aggregate size and stability [35], and may
play an important role in the pathogenesis of inflam-
mation and thrombosis [35]. Subsequently, a decrease in
P-selectin expression on platelet surface after treatment
with liraglutide may predict a favourable CV outcome.
However, the changes in platelet function noted in this
study may also be related to the associated weight
loss. Weight loss has been found to reduce urinarythromboxane A2 metabolites excretion [27] and improve
platelet sensitivity to PGI2 in simple obesity [9]. The im-
provement in platelet function with weight loss was re-
lated to a reduction in abdominal obesity and associated
reduction in IR, inflammation and oxidative stress levels
[9,27]. Platelets have been found to express the insulin
receptor [36] and while insulin is believed to reduce
platelet sensitivity to aggregating agents, its function in
IR states for example type 2 diabetes and obesity is
thought to be impaired [37]. As PCOS, similar to type 2
diabetes, is associated with increased IR independent of
obesity, it is possible that platelets from women with
PCOS are more resistant to the inhibitory effects of lira-
glutide, and/or associated weight loss, perhaps sugges-
ting an inherent defect in platelet function in PCOS.
However, it is worth noting that between group compa-
risons were not significant and it is possible that the lack
of significant change in basal platelet P-selectin ex-
pression in the PCOS group after treatment is related to
higher than anticipated dropout during the study. While
it is still not known if platelets express the GLP-1 recep-
tor, the changes in platelet function noted in our study
may still be an independent effect of liraglutide.
There was a significant reduction in clot lysis area, a
complex measure of clot formation, density and lysis po-
tential, after six months treatment with liraglutide in
both groups. The majority of previous studies examining
clot function and fibrinolysis in obesity reported a re-
duction in fibrinogen levels and reduction in plasmino-
gen activator inhibitor-1 (PAI-1) activity after ≥ 5 – 10%
weight loss [38]. Interestingly, fibrinogen levels did not
significantly change in our study after treatment sugges-
ting that the changes in clot structure parameters ob-
served were probably related to other plasma proteins, yet
to be identified; an independent effect of liraglutide; or to
qualitative changes in fibrinogen induced by weight loss.
Liraglutide’s treatment did not change cIMT measure-
ment in either group despite significant reduction in IR.
This is the converse to what was reported by Orio et al.
[39] who treated 30 lean women with PCOS with met-
formin for six months and found a significant reduction
in cIMT related to an improvement in IR. In another
study [40], weight loss of 3.9 kg/m2 over one year of
dietary and lifestyle intervention in obese adolescent
girls with PCOS resulted in a significant reduction in
cIMT. The change in BMI in our study was smaller,
1.0 – 1.4 kg/m2, the follow up duration was shorter, and
no diet and/or exercise interventions were included
which may account for the discrepancy.
Endothelial function measured by post-ischaemic RHI
was unchanged following liraglutide therapy that was dis-
cordant to the significant reduction in the endothelial
serum adhesion markers sP-selectin, sVCAM, and sICAM.
This is in accord with other studies showing that changes
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response to moderate weight loss do not always cor-
relate. Keogh et al. reported significant improvement in
sP-selectin and sICAM-1 but no change in FMD at
8 weeks despite 5-10% weight loss [41]. In another study,
no change in FMD was noted despite 4 – 8% weight loss
in a large cohort of obese subjects over two year period
[42]. Conversely, weight loss was associated with a reduc-
tion in cIMT and improvement in FMD at 18 months and
5 years of follow up following bariatric surgery [43]. This
suggests that serum markers of endothelial function are
probably more sensitive to small changes in body weight,
inflammation and oxidative stress that do not reflect overt
functional endothelial changes.
Although treatment with liraglutide, in our study, has
resulted in significant reduction in fasting plasma glu-
cose, insulin, and insulin resistance (HOMA-IR), there
was no improvement in β cell function (HOMA-β).
Preclinical studies suggest that liraglutide treatment in-
creases β cells mass [44]. Treatment with liraglutide, in a
20 week trial, increased HOMA-β by 5 – 24% in obese
men and women [13]. The study included more partici-
pants (90 per group) than ours, which may explain the
different results. Interestingly, there was no association
between the dose of liraglutide and the change in β-cell
function after treatment (median increase by 27.8% for
liraglutide 1.8 mg od and 8.4% for 2.4 mg od), nor did
the changes in HOMA-β correlate with HOMA-IR
(which did not change during the study) [13]. It is worth
noting that HOMA-β, although simple and commonly
used, has many limitations including the use of a fasting
parameter of β-cell function, which reflects basal rather
than glucose-stimulated insulin secretion, and is also
affected by alterations in insulin clearance [45-47].
Our data suggest a potential CV benefit for obese
women treated with liraglutide; though how much of the
changes observed during the study were related to the
effects of liraglutide per se or to the associated weight
loss remains unclear. Animal studies suggest that liraglu-
tide may have a cardioprotective effect independent of
weight loss [48].
The strengths of this study include having obese women
with PCOS and controls who had similar age, weight,
BMI and waist circumference; the use of well-established
markers to assess atherothrombotic risk; and the first
study to assess the effects of treatment with GLP-1
analogue on platelet function in obese women with and
without PCOS. The main limitation to our study was the
higher than anticipated dropout during the study which
may have compromised the study power. We are aware
that interpretation of non-significant findings is challen-
ging. Another limitation is the absence of a placebo-
treated group, with equal amount of weight loss achieved,
to clarify if the changes observed were related toliraglutide per se or to the associated weight loss. In
addition, the absence of a placebo treated group makes it
difficult to completely exclude an effect of time, i.e. if the
change in weight was related to regression to the mean
rather than treatment with liraglutide. However, the re-
sults of this study would now allow a larger study to be
powered appropriately to include a placebo.Conclusions
Six months treatment with liraglutide, equally affected
young obese women with PCOS and controls, and was
associated with mild degree of weight loss (3 – 4%) and
significant reduction in IR, inflammation, and oxidative
stress. In both groups, several markers of atherothrom-
bosis also equally improved including markers of endo-
thelial function and clot structure, but no change in
cIMT was observed. While basal platelet activation was
only reduced in the control group, the between groups
difference was not significant. Our data support the use of
liraglutide as weight loss medication in simple obesity and
suggest a potential beneficial effect on platelet function
and atherothrombotic risk at 6 months of treatment.
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